Dr. Dmitrij Hristodorov Director

Dmitrij is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as a board member for ARMGO Pharma and Complement Therapeutics, and as a board observer for VectorY. He previously served as a board observer and R&D committee member of Gyroscope Therapeutics, which was acquired by Novartis for up to $1.5bn.

Scroll to Top